| Abstrakt: |
A recent study conducted by researchers at Mayo Clinic in Rochester, Minnesota, examined the safety and efficacy of lurbinectedin as a treatment option for relapsed small cell lung cancer (SCLC) in a real-world setting. The study included 50 patients who received lurbinectedin as a second-line agent and 14 patients who received it as a third-line or later agent. The results showed that lurbinectedin was generally well tolerated, with a median overall survival of 5.1 months in the second-line cohort and 5.6 months in the third-line or later cohort. The study concluded that while lurbinectedin demonstrated modest efficacy and a comparable safety profile to that observed in clinical trials, outcomes for relapsed SCLC remain suboptimal. [Extracted from the article] |
